Jo Brewer

Chief Scientific Officer • AdaptImmune

Dr Jo Brewer has served as Chief Scientific Officer since May 2022, leading Adaptimmune’s Research division to generate innovative cell therapies for people with cancer.

Jo has more than 20 years of experience in immunotherapy research across the breadth of discovery in both autologous and allogeneic platforms. She was one of the founding scientists at Adaptimmune, who built multiple research teams working on the early SPEAR T-cell therapies including NY-ESO (transitioned to GSK), ADP-A2M4 and ADP-AFP, early next-gen approaches, including ADP-A2M4CD8, as well as her more recent focus on a stem cell derived allogeneic platform.
Prior to joining Adaptimmune in 2009, Jo held positions at Avidex, Medigene and Immunocore. She holds a master’s degree in Natural Sciences and a PhD in cellular signalling, both from the University of Cambridge, UK.

Also Speaking

Christian Aguilera-Sandoval

Applications Manager • Accellix

Chris McClain

Senior Vice President of Sales and Business Development  • Be The Match BioTherapies

Serene Forte

Senior Vice President and Head of Genetic Medicine • RELIEF Therapeutics

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.